Advertisement
News
Advertisement

Third Rock Ventures launches Blueprint Medicines with $40M

Mon, 04/11/2011 - 6:37am
Mass High Tech: The Journal of New England Technology

Blueprint Medicines, a Cambridge early-stage cancer therapeutics firm, has scored a $40 million Series A funding round from Boston’s Third Rock Ventures, the largest A round financing the venture capital firm has ever made.

The startup plans to use the funds and its own compound library and Insights-to-Validation platform to develop personalized treatments based on targeted molecular aberrations of cancer.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading